HSC835
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Single Umbilical Cord Blood Transplantation
Conditions
Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia
Trial Timeline
Oct 7, 2014 → Aug 29, 2016
NCT ID
NCT01930162About HSC835
HSC835 is a phase 2 stage product being developed by Novartis for Single Umbilical Cord Blood Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01930162. Target conditions include Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01930162 | Phase 2 | Completed |
| NCT01474681 | Phase 1/2 | Completed |
Competing Products
2 competing products in Single Umbilical Cord Blood Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dexmedetomidine | Orion Corporation | Phase 3 | 74 |
| Bone Repair Cells (BRCs) | Vericel | Phase 1/2 | 36 |